RESEARCH ARTICLE

Relationship between Breast Cancer and Oral Contraceptive Use among Thai Premenopausal Women: a Case-control Study

Wisit Chaveepojnkamjorn1*, Natchaporn Pichainarong2, Rungsinoppadol Thotong3, Pratana Sativipawee4, Supachai Pitikultang5

Abstract

**Background:** Breast cancer (BC) is an important issue both in medicine and public health as it is the leading malignancy with high incidence and mortality among women worldwide. The objective of this research was to determine the associations of BC with oral contraceptive (OC) use among Thai premenopausal women (TPW).

**Materials and Methods:** A case-control study was conducted among TPW attending the National Cancer Institute, with 257 cases and 257 controls in 2013-2014. Cases and controls were matched by age (± 5 years), residential area and duration of attendance. Data were collected with a questionnaire that comprised 2 sections: part 1 socio-demographic characteristics, and part 2 health risk behavior and reproductive factors. The obtained data were analyzed using descriptive and analytic statistics with a computerized statistical package.

**Results:** The study participants were mainly 40-44 years old (60 %) with an average age of 39 years. The major BC type was invasive ductal carcinoma (91.8%). Multiple unconditional logistic regression analysis, controlling for possible confounding factors, revealed that TPW with OC use increased the risk of BC by a factor of over 3 times (ORadj=3.39, 95%CI =1.99-5.75). In addition, the greater the duration of OC, the greater the risk (ORadj 6-10 yrs=3.91, 95%CI = 1.99-7.64, ORadj >10 yrs=4.23, 95%CI = 2.05-8.71).

**Conclusions:** From our findings, a surveillance system of cancer risk with OC use should be conducted, accompanied by an exercise promotion campaign among risk groups, providing information and counseling for physical exercise and physical activities, weight control and basic adjustment for a healthy lifestyle to reduce BC.

**Keywords:** Breast cancer- oral contraceptive use, Thai premenopausal women

Introduction

Cancers are the top leading cause of death. According to estimates of The World Health Organization (WHO), approximately 8.2 million cancer deaths occurred in 2014 and mortality mainly occurred in developing countries. Of these, 3.4 million are male and female 3.3 million. Almost 70 % of all cancers was seen in underdeveloped and developing countries (Siegel et al., 2015). At present, it is well established that BC is the most commonly diagnosed invasive cancer and the leading cause of cancer death among women worldwide including in Thailand (Siegel et al., 2015; National Cancer Control Committee, 2013; Bureau of Policy and Strategies, 2011; Bureau of Policy and Strategies, 2015). Causes of being BC are likely to be multifactorial. Some studies found that OC use is one of the risk factors of BC (Soroush et al., 2016; Rosenberg et al., 2009). The association between OC use and BC risk has been examined in numerous studies, mainly in western countries. In Thailand, there are quite very few studies of this association among premenopausal women.

The present study was carried out to assess the association between OC use and BC occurrence among TPW.

Materials and Methods

**Study Design, Sample Size and Sampling Technique**

A hospital based case-control study (1:1) was performed at the National Cancer Institute in Bangkok during November 2013 - December 2014 to determine the effect of OC use and BC risk among TPW. A total of 257 BC cases and 257 controls were included in the study. The cases were newly diagnosed with breast cancer by pathologists. The controls were healthy TPW who had annual health check-up. Cases and controls were matched (1:1) by age (+5 years), residential area and duration of attending. Of the 514 women were both premenopausal and aged <45 years at the time of study. The cases and controls were matched (1:1) at the time of match. The cases had annual health check-up. Cases and controls were matched (1:1) by age (+5 years), residential area and duration of attending. Of the 514 women were both premenopausal and aged <45 years at the time of study. Cases and controls used the same questionnaire to obtain data collection.

The sample size was calculated by the formula (Lwanga and Lemeshows, 1991). Where Po = proportion of exposure in controls = 0.32 (Umpan, 2004); P1 = proportion of

1Department of Epidemiology, 2Department of Biostatistics, 3Department of Family Health, Faculty of Public Health, Mahidol University, Ratchathewi, 4Research and Technology Assessment Division, National Cancer Institute, Bangkok, 5Faculty of Public Health, Mahasarakham University, Kantharawichai, Maha Sarakham, Thailand. *For Correspondence: wisit.chai@mahidol.ac.th

Asian Pac J Cancer Prev, 18 (5), 1429-1433
exposure in cases = 0.68 (Umpan, 2004); Z = 2 = 1.96 at α = 0.05; Zβ = 0.84 at β = 0.20; and P = 0.5. The calculated sample size in each group was at least 256.

**Tool and Measurements**

Data collection was obtained by interviewing the study subjects by researcher and trained research assistants. The questionnaire comprised socio-demographic factors, health risk behaviors, reproductive factors, obesity and cancer status. While BC information was collected by laboratory and pathological results, namely, TNM classification, stage of disease, hormone receptor test, and date of diagnosis with BC.

**Variable definitions**

Premenopausal women were defined as those still having menstrual cycles at the time of study.

**Ethical Considerations**

The study was reviewed and approved by the Ethics Committee for research of National Cancer Institute, Ministry of Public Health (148/2556) and the Ethics Committee for Research in Human Subjects of the Faculty of Public Health, Mahidol University (Ref No. MuPH 2014-090) and agreed with the Helsinki declaration. All participants participated in this study are on a voluntary basis. Informed consent to participate in the study was obtained from participants after providing sufficient information. Information was collected by a self-administered questionnaire with the help and supervision of research assistants. Confidentiality was well kept throughout the study using anonymous technique (respondents were identified by code numbers to ensure confidentiality and the results were analyzed as a whole).

**Statistical Analyses**

The data were analyzed with SPSS version 18 (IBM, NY, USA). Categorical variables were given as a frequency and percentage, crude odds ratio, 95% Confidence Interval (CI) of OR and p-value. The numerical variables were expressed as mean, minimum and maximum, and standard deviation (SD). Univariate analysis was performed using the chi-square test to differentiate proportional exposures between BC patents and controls for categorical variables. Adjusted odds ratio and the 95% CI of OR were calculated from multiple unconditional logistic regression to examine associations between BC occurrence and BMI, adjusted for potential confounding factors of reproductive factors and health risk behaviors. A p-value of < 0.05 was considered to be statistically significant.

**Results**

**Demographic Characteristics of Cases and Controls**

A total of 514 TPW participated in the case-control study (1:1). The average age of subjects was 39 years. Table 1 outlines the socio-demographic characteristics of them. To summarize majority of them were aged 40-44 years (59.9%, 61.1%), married (61.8%, 60.7%), higher education (39.7%, 51.4%), buddhism (96.5%, 96.1%), living in central region (68.5%), office employee (35.8%, 32.7%). There was no significant difference regarding demographics among cases and controls (p>0.05).

| Characteristics | Cases % | Controls % | p value |
|-----------------|---------|------------|---------|
| Age gr. (yrs)   |         |            |         |
| ≤ 29            | 10      | 3.9        | 11      | 4.3    | 0.981 |
| 30-34           | 30      | 11.7       | 28      | 10.9   |
| 35-39           | 63      | 24.5       | 61      | 23.7   |
| 40-44           | 154     | 59.9       | 157     | 61.1   |
| Mean (SD)       | 39.20   | 39.30      |        |
| (4.39)          | (4.41)  |            |         |
| Min-Max         | 25-44   | 25-44      |         |
| Marital status  |         |            | 0.07    |
| Single          | 68      | 26.5       | 84      | 32.7   |
| Married         | 159     | 61.8       | 156     | 60.7   |
| Widowed/Divorced| 30      | 11.7       | 17      | 6.6    |
| Education       |         |            | 0.068   |
| No formal ed     | 10      | 3.9        | 8       | 3.1    |
| Primary school  | 67      | 26.1       | 52      | 20.2   |
| Secondary school| 78      | 30.3       | 65      | 25.3   |
| Higher education| 102     | 39.7       | 132     | 51.4   |
| Religion        |         |            | 0.689   |
| Buddhism        | 248     | 96.5       | 247     | 96.1   |
| Islam           | 7       | 2.7        | 6       | 2.3    |
| Christianity    | 2       | 0.8        | 4       | 1.6    |
| Residence       |         |            | 1       |
| North           | 1       | 0.4        | 1       | 0.4    |
| Northeast       | 11      | 4.3        | 11      | 4.3    |
| Central         | 176     | 68.5       | 176     | 68.5   |
| East            | 16      | 6.2        | 16      | 6.2    |
| West            | 48      | 18.7       | 48      | 18.7   |
| South           | 5       | 1.9        | 5       | 1.9    |
| Occupation      |         |            | 0.668   |
| Office employee | 92      | 35.8       | 87      | 33.8   |
| Entrepreneur    | 77      | 30         | 85      | 33.1   |
| Government officer | 73 | 28.4        | 75      | 29.2   |
| Agriculture     | 15      | 5.8        | 10      | 3.9    |
| Monthly family income (baht) | 0.066 |
| < 10,000        | 38      | 14.8       | 34      | 13.2   |
| 10,000-15,000   | 52      | 20.2       | 48      | 18.7   |
| 15,001-30,000   | 138     | 53.7       | 124     | 48.2   |
| >30,000         | 29      | 11.3       | 51      | 19.9   |
| Mean(SD)        | 22,740.08 (9,311.92) | 24,174.32 (13,541.38) |
| Min-Max         | 7,000-70,000 | 7,800-95,000 |

*, chi-square test
Relationship between Breast Cancer and Oral Contraceptive Use among Thai Premenopausal Women: a Case-control Study

Using a univariate analysis, we found that risk factors of developing BC among TPW were family history of BC, history of benign breast tumor, younger age at menarche, parity, miscarriage, OC use, passive smoking, multivitamin use and BMI (p<0.05) as shown in Table 2. Using a multiple unconditional logistic regression analysis, OC use showed the association with BC occurrence after controlling for possible confounding factors (family history of BC, history of benign breast tumor, younger age at menarche, parity, miscarriage, BMI, passive smoking, and multivitamin use). Risk of developing BC with OC use was 3.39 and times (OR_{adj} = 3.39, 95%CI=1.99-5.75), When considering the duration of OC use, the more exposed, the more being BC (OR_{adj} 6-10 yrs=3.91, 95%CI = 1.99-7.64, OR_{adj} >10 yrs=4.23,

Table 2. Crude Analysis of Characteristics associated with BC among TPW

| Characteristics                        | Cases No. | %   | Controls No. | %   | ORc  | 95%CI      | p-value* |
|----------------------------------------|-----------|-----|--------------|-----|------|------------|----------|
| Family history of BC                   | No        | 211 | 82.1         | 249 | 96.9 | 1.00       |          |
|                                       | Yes       | 46  | 17.9         | 8   | 3.1  | 6.79       | 3.13-14.69 | <0.001* |
| History of benign breast tumor         | No        | 209 | 81.3         | 235 | 91.3 | 1.00       |          |
|                                       | Yes       | 48  | 18.7         | 22  | 8.6  | 2.45       | 1.43-4.20  | 0.001*  |
| Age at menarche (yrs)                  | ≥14       | 83  | 32.3         | 140 | 54.5 | 1.00       |          |
|                                       | <14       | 174 | 67.7         | 117 | 45.5 | 2.51       | 1.75-3.59  | <0.001* |
| Parity                                 | No        | 193 | 75.1         | 172 | 66.9 | 1.00       |          |
|                                       | Yes       | 64  | 24.9         | 85  | 33.1 | 0.67       | 0.45-0.99  | 0.041*  |
| Miscarriage                            | No        | 186 | 72.4         | 214 | 83.3 | 1.00       |          |
|                                       | Yes       | 71  | 27.6         | 43  | 16.7 | 1.90       | 1.21-2.98  | 0.003*  |
| OC use                                 | No        | 90  | 35           | 162 | 63.0 | 1.00       |          |
|                                       | Yes       | 167 | 65           | 95  | 37.0 | 2.11       | 2.21-4.54  | <0.001* |
| Duration of OC use (yrs)               | 0         | 90  | 35           | 162 | 63.0 | 1.00       |          |
|                                       | 1-5       | 42  | 16.3         | 44  | 17.1 | 1.72       | 1.01-2.90  | 0.031*  |
|                                       | 6-10      | 70  | 27.2         | 30  | 11.7 | 4.2        | 2.48-7.17  | <0.001* |
|                                       | >10       | 55  | 21.5         | 21  | 8.2  | 4.71       | 2.59-8.72  | <0.001* |
| Active smoking                         | No        | 248 | 96.5         | 251 | 97.7 | 1.00       |          |
|                                       | Yes       | 9   | 3.5          | 6   | 2.3  | 0.53       | 0.53-3.33  | 0.432   |
| Passive smoking                        | No        | 153 | 59.5         | 198 | 77.1 | 1.00       |          |
|                                       | Yes       | 104 | 40.5         | 59  | 22.9 | 2.28       | 1.53-3.41  | <0.001* |
| Alcohol consumption                    | No        | 251 | 97.7         | 252 | 98.1 | 1.00       |          |
|                                       | Yes       | 6   | 2.3          | 5   | 1.9  | 0.32       | 0.32-4.61  | 0.761   |
| Multivitamin use                       | No        | 227 | 88.3         | 168 | 65.4 | 1          |          |
|                                       | Yes       | 30  | 11.7         | 89  | 34.6 | 0.25       | 0.15-0.40  | <0.001* |
| Body mass index (kg/m^2)               | 18.5-22.9 | 89  | 34.7         | 122 | 47.4 | 1.00       |          |
|                                       | 23.0-24.9 | 44  | 17.1         | 54  | 21.0 | 1.12       | 0.67-1.86  | 0.629   |
|                                       | 25.0-29.9 | 88  | 34.2         | 41  | 16.0 | 2.94       | 1.81-4.79  | <0.001* |
|                                       | ≥30.0     | 26  | 10.1         | 10  | 3.9  | 3.56       | 1.55-8.38  | <0.001* |
|                                       | <18.5     | 10  | 3.9          | 30  | 11.7 | 0.46       | 0.20-1.05  | 0.056   |

*, chi-square test, ORc= crude odds ratio, CI= confidence interval; *, significant at p-value <0.05.

BC and Risk Factors

Using a univariate analysis, we found that risk factors of developing BC among TPW were family history of BC, history of benign breast tumor, younger age at menarche, parity, miscarriage, BMI, passive smoking, and multivitamin use. Risk of developing BC with OC use was 3.39 and times (OR_{adj} = 3.39, 95%CI=1.99-5.75), When considering the duration of OC use, the more exposed, the more being BC (OR_{adj} 6-10 yrs=3.91, 95%CI = 1.99-7.64, OR_{adj} >10 yrs=4.23,
Table 3. Multivariable Logistic Regression Analysis of OC use associated with BC among TPW

| Variables               | OR       | 95%CI       | OR_adj  | 95%CI       | p-value  |
|-------------------------|----------|-------------|---------|-------------|----------|
| OC use                  |          |             |         |             |          |
| No                      | 1        | 1           | 1       |             |          |
| Yes                     | 3.16     | 2.21-4.54   | 1.99-5.75 | <0.001*    |          |
| Duration of OC use (yrs)|          |             |         |             |          |
| 0                       | 1        | 1           | 1       |             |          |
| 1-5                     | 1.72     | 1.01-2.90   | 0.90-3.25 | 0.099      |          |
| 6-10                    | 2.48     | 2.48-7.17   | 3.91     | 1.99-7.64   | <0.001*  |          |
| >10                     | 4.71     | 2.59-8.72   | 4.23     | 2.05-8.71   | <0.001*  |          |

OR, crude OR; OR_adj, adjusted OR for family history of BC; history of benign breast tumor, age at menarche, parity, miscarriage, passive smoking, multivitamin use and BMI; *, significant at p-value <0.05.

95%CI = 2.05-8.71) as shown in Table 3.

Discussion

Study participants were the TPW, mostly aged 40-44 years (60%). Socio-demographic characteristics of cases and controls were quite alike. When controlled by health risk behaviors and reproductive factors, found that TPW with OC use was being BC risks. Our findings indicated that women with OC use were about 3 times risk to develop BC. It was consistent with the previous studies (Soroush et al., 2016; Rosenberg et al., 2009; Nyante et al., 2008; Kahlenborn et al., 2006; Newcomer et al., 2003; Hemminki et al., 2002; Grabeck et al., 2000), meanwhile some studies showed the contrary results (Haile et al., 2006; Silvera et al., 2005; Mine et al., 2005; Jernstrom et al., 2005; Tessaro et al., 2001; Van Hoften et al., 2000).

The reason to support the association owing to estrogen hormone in OC pills, therefore it will have a cohesion with specific receptor on cancer cell’s surface and then it will send the biochemical signals and activate cell multiplication (Howlader et al., 2016). The association had no evidence in OC use with only progesterone (McNaught et al., 2006). In addition, the present studies revealed the risk of BC had increased according to duration of OC use and it’s consistent with some studies (Howlader et al., 2016; Collaborative Group on Hormonal Factors in Breast Cancer, 1996). Therefore, birth control with BC patients should be namely, contraceptive pills with progesterone, depot medroxyprogesterone acetate injection, intrauterine device (IUD) with progesterone, and so on (Kabos and Borges, 2011). In addition, breast self examination is very necessary, so women should be done correctly (Smith et al., 2003). For women ≥ 40 years should be checked up with mammogram annually (Smith et al., 2003; American College of Radiology, 2013). There are a lot of tools for BC risk evaluation, such as the Gail Model, the Claus Model, the Tyree-Cuzick Model and the BRCAPRO model (Santen et al., 2007; Hollingsworth et al., 2004). For Thais, campaign of women aged ≥ 20 years to examine by themselves, they should be aware of advantages and limitations of this technique, support breast feeding after give birth 6 months, reduce alcohol consumption and reduce obesity (National Cancer Control Committee, 2013). Therefore, the surveillance of cancer risk and contraceptive use is the crucial measure to reduce BC risks.

Advantages and limitation of the Study

There are some advantages of this case-control study. First, the National Cancer Institute is the specialized hospital for cancer patients. Second, they are easily identified, and provide sufficient numbers. Finally, cases are newly BC patients diagnosed and confirmed by pathologists, which lead to the reduction in classification bias. Some limitations of this study should be noted. First, the study was a hospital based case-control study, therefore, the representative of target population couldn’t be mentioned. Second, it was very difficult to select the suitable controls. However, we matched cases and controls by age, residence and duration of attending. In summary, it should be the surveillance system of cancer risks and OC use and campaign of cancer prevention such as proper exercise, healthy diet, weight control and basic methods for health lifestyle among risk groups (National Cancer Control Committee, 2013), it will minimize and reduce risks of developing BC.

Acknowledgements

We would like to express sincere thanks to the participants and staff for their valuable participation in the study. We also wish to extend our deep appreciations to those who are not mentioned here for their kindness and encouragement. This study was supported for publication by the China Medical Board (CMB) Faculty of Public Health, Mahidol University, Bangkok, Thailand.

References

American college of radiology (2013). ACR practice parameter for the performance of screening and diagnostic mammography. revised 2013. Available from https://www.acr.org/-/media/scr/3484eca30845348359bad4684779d492d.pdf.

Bureau of policy and strategies, Ministry of public health (2011). Thailand health profile 2008-2010. Bangkok: The war Veterans organization of Thailand.

Bureau of policy and strategies, Ministry of public health (2015). Public health statistics 2014. Bangkok: The war Veterans organization of Thailand.

Collaborative group on hormonal factors in breast cancer (1996). Breast cancer and hormonal contraceptives: collaborative reanalysis of individual data on 53297 women with breast cancer.
cancer and 100239 women without breast cancer from 54 epidemiological studies. *Lancet*, **347**, 1713-27.

Grabrick DM, Hartmann LC, Cerhan JR, et al (2000). Risk of breast cancer with oral contraceptive use in women with a family history of breast cancer. *JAMA*, **284**, 1791-8.

Haile RW, Thomas DC, McGuire V, et al (2006). BRCA1 and BRCA2 mutation carriers, oral contraceptive use, and breast cancer before age 50. *Cancer Epidemiol Biomarkers Prev*, **15**, 1863-70.

Hemminki E, Luostarinen T, Pukkala E, et al (2002). Oral contraceptive use before first birth and risk of breast cancer: a case control study. *BMC Women’s Health*, **2**, 9.

Hollingsworth AB, Singletary SE, Morrow M, et al (2004). Current comprehensive assessment and management of women at increased risk for breast cancer. *Am J Surg*, **187**, 349-62.

Howlader N, Noone AM, Krapcho M, et al (2016). SEERcancer statistics review, 1975-2013, National cancer institute. Bethesda, MD, [http://seer.cancer.gov/csr/1975_2013/](http://seer.cancer.gov/csr/1975_2013/), based on November 2015 SEER data submission, posted to the SEER web site, April 2016.

Jernstrom H, Loman N, Johannsson OT, et al (2005). Impact of teenage oral contraceptive use in a population-based series of early-onset breast cancer cases who have undergone BRCA mutation testing. *Eur J Cancer*, **41**, 2312-20.

Kabos P, Borges VF (2011). Surveillance and detection of recurrence of breast cancer. In ‘Jacobs L, Finlayson CA’, Eds. Early diagnosis and treatment of cancer: breast cancer. Philadelphia: Saunders Elsevier, pp 307-18.

Kahlenborn C, Modugno F, Potter DM, et al (2006). Oral contraceptive use as a risk factor for premenopausal breast cancer: a meta-analysis. *Mayo Clin Proc*, **81**, 1290-302.

Kwanga SK, Lemeshow S (1991). Sample size determination in health studies: a practical manual. Geneva: World Health Organization.

McNaught J, Reid RL, Provencher DM, et al (2006). Progesterone-only and non-hormonal contraception in the breast cancer survivor: Joint review and committee opinion of the society of obstetricians and gynaecologists of Canada and the society of gynecologic oncologists of Canada. *J Obstet Gynaecol Can*, **28**, 616-39.

Milne RL, Knight JA, John EM, et al (2005). Oral contraceptive use and risk of early-onset breast cancer in carriers and noncarriers of BRCA1 and BRCA2 mutations. *Cancer Epidemiol Biomarkers Prev*, **14**, 350-6.

National cancer control committee, Department of health, ministry of public health (2013). National cancer control programmes 2013-2017. Bangkok: The agricultural cooperative printing of Thailand.

Newcomer LM, Newcomb PA, Trentham-Dietz A, et al (2003). Oral contraceptive use and risk of breast cancer by histologic type. *Int J Cancer*, **106**, 961-4.

Nyante SJ, Gammon MD, Malone KE, et al (2008). The association between oral contraceptive use and lobular and ductal breast cancer in young women. *Int J Cancer*, **122**, 936-41.

Rosenberg L, Zhang Y, Coogan PF, et al (2009). A case-control study of oral contraceptive use and incident breast cancer. *Am J Epidemiol*, **169**, 473-9.

Santen RJ, Boyd NF, Chlebowski RT, et al (2007). Critical assessment of new risk factors for breast cancer: considerations for development of an improved risk prediction model. *Endocr Relat Cancer*, **14**, 169-87.

Siegel RL, Miller KD, Jemal A (2015). Cancer statistics. *CA Cancer J Clin*, **65**, 5-29.

Silvera SA, Miller AB, Rohan TE (2005). Oral contraceptive use and risk of breast cancer among women with a family history of breast cancer: a prospective cohort study. *Cancer Causes Control*, **16**, 1059-63.

Smith RA, Saslow D, Sawyer KA, et al (2003). American cancer society guidelines for breast cancer screening: update 2003. *CA Cancer J Clin*, **53**, 141-69.

Soroush A, Farshchian N, Komasi S, et al (2016). The role of oral contraceptive pills on increased risk of breast cancer in Iranian populations: a meta-analysis. *J Cancer Prev*, **21**, 294-301.

Tessaro S, Beria JU, Tomasi E, et al (2001). Oral contraceptive and breast cancer: a case-control study. *Revista de saúde publica*, **35**, 32-8.

Umpan W (2004). Relation between oral contraceptive use and breast cancer in women [Thesis]. Bangkok: Mahidol University.

Van Hoften C, Burger H, Peeters PH, et al (2000). Long-term oral contraceptive use increases breast cancer risk in women over 55 years of age: the DOM cohort. *Int J Cancer*, **87**, 591-4.